At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PLRZ Polyrizon Ltd.
Closed 01-08 16:00:00 EST
1.54
-0.05
-3.14%
盘后1.48
-0.06-3.90%
19:44 EST
High1.59Low1.45Vol172.26K
Open1.59D1 Closing1.59Amplitude8.81%
Mkt Cap6.46MTradable Cap1.54MTotal Shares4.19M
T/O263.98KT/O Rate17.23%Tradable Shares1.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BRIEF-Polyrizon Ltd Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC Filing
Reuters  ·  2024-12-31
BRIEF-Polyrizon Ltd Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC Filing
Polyrizon files to sell 2.42M ordinary shares for holders
TIPRANKS  ·  2024-12-31
Polyrizon files to sell 2.42M ordinary shares for holders
Polyrizon Ltd: Files Prospectus Related to Resale by Selling Shareholders of up to 2.4 Mln Ordinary Shares - SEC Filing
THOMSON REUTERS  ·  2024-12-31
Polyrizon Ltd: Files Prospectus Related to Resale by Selling Shareholders of up to 2.4 Mln Ordinary Shares - SEC Filing
Polyrizon Shares Rise After Publication of National Patent Application
Dow Jones  ·  2024-12-30
Polyrizon Shares Rise After Publication of National Patent Application
Risk Aversion Grips Wall Street in Penultimate Session of 2024, Fueling Premarket Losses for US Equity Futures
MT Newswires Live  ·  2024-12-30
Risk Aversion Grips Wall Street in Penultimate Session of 2024, Fueling Premarket Losses for US Equity Futures
Polyrizon Files US Patent Application for Nasal Drug Delivery Platforms; Shares Jump Pre-Bell
MT Newswires Live  ·  2024-12-30
Polyrizon Files US Patent Application for Nasal Drug Delivery Platforms; Shares Jump Pre-Bell
Top Premarket Gainers
MT Newswires Live  ·  2024-12-30
Top Premarket Gainers
Polyrizon announces publication of patent application for hydrogel nasal tech
TIPRANKS  ·  2024-12-30
Polyrizon announces publication of patent application for hydrogel nasal tech
Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs
TIPRANKS  ·  2024-12-19
Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs
Polyrizon Appoints DR. Michal Meir as Senior Director of Regulatory and Clinical Affairs
THOMSON REUTERS  ·  2024-12-19
Polyrizon Appoints DR. Michal Meir as Senior Director of Regulatory and Clinical Affairs
Press Release: Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
Dow Jones  ·  2024-12-19
Press Release: Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
Polyrizon Shares Surge on Impending Clinical Trial
Dow Jones  ·  2024-12-19
Polyrizon Shares Surge on Impending Clinical Trial
Polyrizon Collaborating With Eurofins CDMO for Clinical Trial of Allergy Blocker; Shares Jump
MT Newswires Live  ·  2024-12-18
Polyrizon Collaborating With Eurofins CDMO for Clinical Trial of Allergy Blocker; Shares Jump
Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for Its Pl-14 Allergy Blocker
THOMSON REUTERS  ·  2024-12-18
Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for Its Pl-14 Allergy Blocker
Polyrizon Announces Appointment of Vp of Regulatory Affairs and Quality Assurance
THOMSON REUTERS  ·  2024-12-13
Polyrizon Announces Appointment of Vp of Regulatory Affairs and Quality Assurance
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
GlobeNewswire  ·  2024-12-13
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
Polyrizon Enters Into Gmp Manufacturing Agreement for Ctm Supply of Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
THOMSON REUTERS  ·  2024-12-02
Polyrizon Enters Into Gmp Manufacturing Agreement for Ctm Supply of Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
ACCESSWIRE  ·  2024-10-31
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
BRIEF-Polyrizon Announces Closing Of $4.2 Mln IPO
Reuters  ·  2024-10-30
BRIEF-Polyrizon Announces Closing Of $4.2 Mln IPO
Polyrizon opens at $1.64, IPO priced at $4.38 per unit
TIPRANKS  ·  2024-10-30
Polyrizon opens at $1.64, IPO priced at $4.38 per unit

Introduction

Company Name.
Polyrizon Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--